{"disease":{"id":"b-cell-malignancy","name":"b cell malignancy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07474051","title":"Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":178,"lead_sponsor_name":"AvenCell Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05294731","title":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT04035434","title":"A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":93,"lead_sponsor_name":"CRISPR Therapeutics AG","has_results":true},{"nct_id":"NCT06634589","title":"A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT06758713","title":"Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"The Third Affiliated Hospital of Southern Medical University","has_results":false},{"nct_id":"NCT04384393","title":"Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Fundamenta Therapeutics, Ltd.","has_results":false},{"nct_id":"NCT06662227","title":"Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Wondercel Biotech (ShenZhen)","has_results":false},{"nct_id":"NCT03449108","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04601181","title":"Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Fundamenta Therapeutics, Ltd.","has_results":false},{"nct_id":"NCT05106946","title":"Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Fundamenta Therapeutics, Ltd.","has_results":false},{"nct_id":"NCT05106907","title":"Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Fundamenta Therapeutics, Ltd.","has_results":false},{"nct_id":"NCT03207178","title":"Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Shanghai Longyao Biotechnology Inc., Ltd.","has_results":false},{"nct_id":"NCT03953599","title":"CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Hebei Yanda Ludaopei Hospital","has_results":false},{"nct_id":"NCT04933825","title":"A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"EdiGene (GuangZhou) Inc.","has_results":false},{"nct_id":"NCT04681105","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03952923","title":"CD19-CAR-T in B-cell Malignancies Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Hebei Yanda Ludaopei Hospital","has_results":false},{"nct_id":"NCT03559439","title":"CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":9,"lead_sponsor_name":"Shanghai Tong Ren Hospital","has_results":false},{"nct_id":"NCT06532630","title":"Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"Shanghai First Song Biotechnology Co., LTD","has_results":false},{"nct_id":"NCT03272633","title":"Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT03739606","title":"Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"City of Hope Medical Center","has_results":false}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}